Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about Retatrutide, the third-generation injectable making waves as the most powerful weight-loss drug studied yet. It targets three hormone pathways at once instead of just one or two, and early trial participants have lost staggering amounts of weight, some over 30 percent of their body weight. But is more always better? Jenn breaks down how this triple mechanism works in the body, what the research shows so far, and why it might finally help the roughly 10 percent of people who never responded to earlier GLP-1s. Still, she has been raising the same concerns since Ozempic first came onto the scene, and this new drug is no exception. Is Retatrutide the breakthrough the weight loss world has been waiting for, or just a stronger version of the same unanswered questions? Tune in to hear Jenn's full take. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/
RESOURCES:
Become a Happy Healthy Hub Member
Jenn’s Free Menu Plan
A Salad With a Side of Fries
A Salad With A Side Of Fries Merch
A Salad With a Side of Fries Instagram
Ozempic
American Diabetes Association
Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMC
Glucagon | Hormones
International Journal of Molecular Sciences
Hyperglycemia vs. Hypoglycemia: Differences in Causes and Symptoms - GoodRx
Glucagon Control on Food Intake and Energy Balance - PMC
Lilly Phase 3 Study
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials - ScienceDirect
Lilly - Retatrutide
What Is Osteoarthritis? Causes, Symptoms, and Treatments - GoodRx
Potential Retatrutide Benefits You Should Know About - GoodRx
Clinical Trials
Study Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.gov
Clinical Trials
Study Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ClinicalTrials.gov
Clinical Trials
NCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | ClinicalTrials.gov
11 GLP-1 Side Effects You Should Know About - GoodRx
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of
Medicine Counterfeit Drugs
Peptides for Weight Loss: What They Are and How They Work - GoodRx
Jenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Retatrutide, Glp 1, Gip, Glucagon, Weight Loss, Ozempic, Wegovy, Mounjaro, Zepbound, Tirzepatide, Semaglutide, Insulin Sensitivity, Gastric Emptying, Appetite Suppression, Blood Sugar Control, A1c, Glycated Hemoglobin, Liver Steatosis, Fatty Liver Disease, Diabetic Kidney Disease, Type 2 Diabetes, Metabolic Dysfunction, Cardiovascular Risk, Osteoarthritis, Bone Density, Muscle Loss, Body Composition, Clinical Trials, Phase Three Trials, Injectable Medication, Weight Loss Drug, Pharmaceutical Intervention, Hunger Hormone, Satiety, Nausea, Constipation, Gastrointestinal Side Effects, Compounding Pharmacy, Counterfeit Medication, Obesity Treatment, Incretin Hormone, Retatrutide Weight Loss Results, Third Generation Glp 1 Medication
